Pituitary & hypothalamus

The usefulness of cannulated prolactin test in mild hyperprolactinemia: case series and systematic review of the literature

PituitaryPublished Retrospective case series and systematic review of the literature

Authors' conclusion

CPT is useful in excluding hyperprolactinemia in more than 50% of mild hyperprolactinemia patients, avoiding unnecessary imaging, overdiagnosis and treatment. More than three-quarters of patients who normalize prolactin during CPT have normal PRL0’.

Study context

Population
Patients with hyperprolactinemia on an initial measurement (referral prolactin, referral prolactin (rPRL)) who underwent cannulated prolactin testing (CPT), 2018–2025; 82% females; mean rPRL 59.5 ± 43.2ng/mL
Participants
105 patients
Outcome
Prolactin normalization during CPT (PRL0’ or nadir PRL within the normal range)
Methodological detailsCatheter inserted; prolactin sampled at baseline (PRL0’), 30 min and 60 min, Literature review: PubMed and Scopus, articles published until 1 October 2025
  • Catheter inserted; prolactin sampled at baseline (PRL0’), 30 min and 60 min
  • Literature review: PubMed and Scopus, articles published until 1 October 2025

Pooled result

As reported in the abstract

Normal prolactin during CPT (case series)

Normal prolactin during CPT

62 of 105

59%

Normal PRL0’ among normalized

47

75.8%

Normalized at 30 min

10

Normalized at 60 min

5

Further pooled results

PRL0’ prediction of normalization

AUC
0.905 (95% CI 0.850-0.960)
Optimal PRL0’ cut-off
30.1ng/mL

Systematic review: prolactin normalization during CPT

Patients analysed from 12 series
1700
Normalized prolactin during CPT
913 (53.7%)
Of these, normal at timepoint 0’
75.3%

Original publication

The usefulness of cannulated prolactin test in mild hyperprolactinemia: case series and systematic review of the literature. Pituitary. Published 12 January 2026. doi:10.1007/s11102-025-01627-9

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.